Blessy M.R et al
IAJPS 2021, 08 (02), 318-323
ISSN 2349-7750
CODEN [USA]: IAJPBB
ISSN : 2349-7750
INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
http://doi.org/10.5281/zenodo.4569362
A Review Article
Avalable online at: http://www.iajps.com
AN OVERVIEW: IMMUNOTOXIN
Blessy M.R*1 , Subash Chandran M.P1, Prasobh G.R1, Remya S.B1, Aparna P1,
Rohini L M 1, Varsha V R1, Archana L R1
Department of Pharmaceutics, Sree Krishna College of Pharmacy and Research Centre,
Parassala, Thiruvananthapuram, Kerala, India. 695502
Article Received: January 2021
Accepted: January 2021
Published: February 2021
Abstract:
Immunotoxins are hybrid molecules composed of a monoclonal antibody chemically linked to a biologic toxin. The
antibody portion of the molecule directs it to a specific antigenic determinant on a target cell; the molecule is then
internalized, and a cytotoxic reaction occurs. First-generation immunotoxins were made by chemically coupling
toxins such as ricin (a plant toxin) or diphtheria toxin to MAbs. The early products were highly immunogenic and
chemically unstable, sometimes falling apart before reaching the tumor target. These difficulties led to the
development of recombinant immunotoxins that were more stably linked to the antibody until bound on the target
cell surface.
Key words: Immunotoxin, Pseudomonous exotoxin, Monoclonal antibody
Corresponding author:
Blessy M.R,
Department of Pharmaceutics,
Sree Krishna College of Pharmacy and Research Centre,
Parassala, Thiruvananthapuram, Kerala, India. 695502
Ph.No: 0471-2204747
E-mail: blessyfinosh@gmail.com
QR code
Please cite this article in press Blessy M.R et al, An Overview: Immunotoxin., Indo Am. J. P. Sci, 2021; 08(02).
www.iajps.com
Page 318
IAJPS 2021, 08 (02), 318-323
Blessy M.R et al
INTRODUCTION:
Immunotoxins are molecules that can bind to specific
target cells and selectively kill them. The specificity
of the reaction with target cells is dependent on the
antibody part and the cytotoxic effect is due to the
toxin moiety. Various toxins have been used for this
purpose but Pseudomonas exotoxin A, plant toxin
ricin, and diphtheria toxin are employed most often.
As targets for immunotoxins, various surface
antigens of tumour cells are applied, including
receptors (e.g., interleukin and growth factor
receptors), differential antigens, and some others.
The first immunotoxins were complexes of antibody
molecules (or their Fab fragments) and purified
toxins attached to each other by chemical linkages.
The conjugates with whole IgG antibodies have long
circulation times in the blood (typically 4–8 hours)
and they have shown in clinical trials inhibitory
activity against leukemias and lymphomas as well as
against solid tumors .More recent constructs are
recombinant molecules made from single chain Fv
antibody fragments and truncated toxins, which lack
the cell-binding domain. They penetrate cells of solid
tumors more easily. However, small immunotoxins
have short survival times (half-life up to 30 minutes).
In some scFv fragments, the peptide link between
VL and VH can interfere with binding and they are not
always stable. Instead, a disulfide bond between
residues in the conserved framework, which were
mutated to cysteines, was used for the preparation of
more stable Fvs (dsFvs).
For wider clinical usage of immunotoxins some
important problems must be solved. The
immunogenicity of immunotoxins, which is
dependent mainly on their toxin part, is one of them.
Another problem that has to be overcome is the
toxicity of immunotoxins. Ricin-based immunotoxins
can cause a capillary leak syndrome and
immunotoxins with Pseudomonas exotoxin A can
damage the liver.
IMMUNOTOXINS
Immunotoxins are a class of proteins that consist of
a monoclonal antibody covalently linked to a toxic
molecule. The toxic protein may be of plant origin,
including ribosome-inactivating
proteins ricin and gelonin. Other toxins widely used
include diptheria toxin, pseudomonas exotoxin,
and calicheamicin.
The
FDA-approved
immunoconjugate CMA-676, used in the treatment
of myeloid leukemia, incorporates calicheamicin,
www.iajps.com
ISSN 2349-7750
which works by creating double-stranded DNA
breaks. Immunotoxins are directed to target antigen
in the same manner as native antibodies, which
consequently makes immunotoxins susceptible to
some of the same mechanisms of resistance affecting
unconjugated antibodies. Immunotoxins must be
specifically targeted to the surface via monoclonal
antibody. Once bound, the immunotoxin will be
internalized via receptor-mediated endocytosis and
delivered into an endosomal compartment. The
immunotoxin will then be trafficked and processed
within the cell until the enzymatically active domain
is translocated into the cytosol before finally reaching
its target. Therefore, mutation, heterogeneity of
expression, or shedding of the target antigen may
contribute to resistance. Shedding of the antigen
target from the surface of the cell or structural
changes in the epitope will prevent antigen
recognition and inhibit immunotoxin binding.
The development of monoclonal antibodies with
unique specificity to tumor antigens has allowed for
multiple attempts to use them as a mode of cancer
therapy. They may either be used alone to mediate
complement-dependent
or
antibody-dependent
cellular cytotoxicity, or they may be linked to
therapeutic drugs or toxins so that the conjugate may
be targeted specifically to cancer cells. In addition to
their relative selectivity and minimal toxicity, they
are easily mass produced for widespread application.
Their success is unfortunately limited by the
relatively low amount of antibody that reaches the
tumor and by their limited ability to destroy tumor
tissue. Murine monoclonal antibodies are often
inactivated by the development of human anti-mouse
antibodies, although recombinant chimeric antibodies
that combine the constant region of human antibodies
with the variable region of mouse antibodies can help
overcome this.
The targeting moiety
The targeting moiety should be able to differentiate
neoplastic cell based on the antigen expression
pattern. There are two classes of targeting moiety.
One group is composed of physiologically important
ligands such as growth factors, cytokines,
lymphokines and poly peptide hormones are other
group consist of monoclonal antibodies.
The toxin moiety
The toxin used to make immunotoxin is a class of
protein toxin. They have extreme potency and ability
to kill drug resistant cell. Plant toxin and bacterial
Page 319
IAJPS 2021, 08 (02), 318-323
Blessy M.R et al
toxin are used as protein toxin. The toxin which used
in brain tumor destruction is pseudomonas exotoxin
(PE), which is a bacterial toxin.
Early Immunotoxin Development
Thorpe et al. set the stage for immunotoxin
development by confirming that protein toxins could
be redirected to kill selected cell types over ystander
cells [2]. However, their result was achieved with a
poorly defined antibody preparation. Using the same
concept but with the benefit of Kohler and Milstein’s
monoclonal antibody technology [3,73], well defined
immunotoxins of a single specificity were produced.
These included, ricin-, DT- and PE-derived
immunotoxins. Besides antibody and toxin selection,
other steps in the manufacture of immunotoxins
included the use of different chemical “glues” (called
cross linkers) to join the two molecules in a manner
that kept both parts functional [74,75]. Early on it
was appreciated that antibodies alone were rarely
cytotoxic. This fueled research into making
antibodies more potent by attaching protein toxins to
them. Potency depended not only on internalization
but also on the “correct” internal conditions within
the cell. For instance, in the case of early
immunotoxins to CD5 made with the T101 antibody,
neutralization of acidic pH was deemed important for
optimal killing [76]. In other immunotoxins, disulfide
linkers allowed for cytotoxic activity while thioether
linkers did not, confirming the need for the
appropriate reducing environment to allow separation
of toxin from antibody [75,77].
For PE the first immunotoxins were made via
thioether linkage from an intact monoclonal antibody
to the native intact toxin (Figure 2B). When the
functions of the toxin’s structural domain were
discovered, it made sense to delete the receptor
binding domain, producing a molecule termed PE40based on its molecular weight. However, the deletion
of the N-terminal domain (harboring many lysine
residues for chemical conjugation) created a problem
of how to attach PE40 to antibodies. This was solved
by the introduction of a novel lysine residue near the
terminus of PE40, producing Lys-PE40 (Figure 2C).
Together, these chemical conjugates made up first
and second generations of immunotoxins.
Toxins2013, 51491
Figure 2. Immunotoxin construction-from oldest to
newest. First generation immunotoxins were
constructed by using chemical crosslinking agents to
www.iajps.com
ISSN 2349-7750
attach intact toxins to intact antibodies. Second
generation immunotoxins used modified toxins
lacking receptor-binding domains. Third generation
molecules used cloned antibody fragments fused to
modified toxin genes; allowing for the recombinant
production of homogeneous protein. Further
improvements of the third generation olecule might
include the removal of immunogenic amino acids
including (as shown) much of the multi-helical
domain of PE.
IMMUNOTOXIN DEVELOPMENT
Immunotoxin development by confirming that
protein toxins could be redirected to kill selected cell
types over bystander cells. However, their result was
achieved with a poorly defined antibody preparation.
Using the same concept but with the benefit of
monoclonal antibody technology well defined
immunotoxins of a single specificity were produced.
These included, ricin-, DT- and PE-derived
immunotoxins. Besides antibody and toxin selection,
other steps in the manufacture of immunotoxins
included the use of different chemical “glues” (called
cross linkers) to join the two molecules in a manner
that kept both parts functional .Early on it was
appreciated that antibodies alone were rarely
cytotoxic. This fueled research into making
antibodies more potent by attaching protein toxins to
them. Potency depended not only on internalization
but also on the “correct” internal conditions within
the cell. For instance, in the case of early
immunotoxins to CD5 made with the T101 antibody,
neutralization of acidic pH was deemed important for
optimal killing. In other immunotoxins, disulfide
linkers allowed for cytotoxic activity while thioether
linkers did not, confirming the need for the
appropriate reducing environment to allow separation
of toxin from antibody. For PE the first
immunotoxins were made via thioether linkage from
an intact monoclonal antibody to the native intact
toxin. When the functions of the toxin’s structural
domain were discovered, it made sense to delete the
receptor binding domain, producing a molecule
termed PE40-based on its molecular weight.
However, the deletion of the N-terminal domain
(harbouring many lysine residues for chemical
conjugation) created a problem of how to attach PE40
to antibodies. This was solved by the introduction of
a novel lysine residue near the terminus of PE40,
producing Lys-PE40. Together, these chemical
conjugates made up first and second generations of
immunotoxins.
Page 320
IAJPS 2021, 08 (02), 318-323
Blessy M.R et al
Immunotoxins are basically composed of two
functional moieties: one is a MAb or Fv portions of
an antibody; another is a plant or bacterial toxin.
MAbs are known to be the most specific agent
against an antigen expressed by cancer cells, while
the toxin part is among the most potent agents against
cancer cells. One single IT molecule can inactivate
over 200 ribosomes or elongation factor-2 molecules
per minute and is potent enough to kill a cell as
compared
to
104–105 molecules
of
a
chemotherapeutic drug that are needed to kill one cell
.
Development of ITs evolves with time and
technology. The first generation of ITs was generated
by coupling a native toxin with a MAb through a
crosslinking reagent that forms disulfide bonds
between the toxin and antibody moieties. However,
native toxins induce severe side effects when given to
humans due to their non-specific binding to normal
cells. Native toxins are commonly composed of three
domains: one is the receptor binding or cell
recognition domain that enables the toxin to bind to
the cell surface; one is the translocation domain that
helps translocation of the A chain into cytosol; and
the third one is the catalytic domain (also called
activity domain or A chain) that exerts cytotoxic
effects on cells upon translocation to the cytosol
www.iajps.com
ISSN 2349-7750
compartment. The binding domains of different
toxins recognize various receptors ubiquitiously on
normal cells. The non-specific binding compromises
the specificity of ITs, and induces severe systemic
side effects. Thereby, toxins were deglycosylated and
the binding domain was deleted when conjugated to
MAbs, which led to the development of second
generation of ITs. As expected, this approach
significantly reduces the non-specific toxicities of
ITs, allowing more ITs to be given to humans.
Although the results were encouraging, some
problems for the second generation ITs persisted,
including: 1) poor stability due to the chemical
crosslinking between antibody and toxin moieties; 2)
heterogeneous composition and reduced binding
affinity caused by the random conjugation; 3) poo3r
penetration to solid tumor mass because of the large
molecular size (>190 kDa); 4) immunogenicity; and
5) limited production.
To improve the pharmacokinetics and reduce the side
effects of ITs, great efforts have then been made to
generate the third generation ITs which is called
recombinant ITs (RITs). Development of RITs is
driven by the ability to genetically design and express
the antibody fragments and toxins with recombinant
DNA techniques. Generally speaking, development
of RITs involves two critical steps: 1) design and
Page 321
IAJPS 2021, 08 (02), 318-323
Blessy M.R et al
construct the recombinant antibody fragments and
mutated PE or DT; and 2) expression and purification
of the constructed products.
IMMUNOTOXINS AND THEIR WORKING
MECHANISM
The dimeric its consist of toxins and monoclonal
antibodies, either as unmodified or modified
molecules, linkes together by a peptide sequence or
by a disulfide bond. The plant and bacterial toxins
used in immunotoxins kill cells byhalting cellular
protein synthesis. Intracellular delivery to the cytosol
is required for antitumor activity. After the
immunotoxin targeting moiety binds to the cancer
cell surface,the molecule is internalised to the
Immunotoxin on melanoma cells is a targeted
approach, theoretically leaving normal cells
unaffected. Even developed to target melanoma cells
demonstrate advantages for several reasons, IT
binding to antigens over expressed though it has not
been investigated, this mechanism of cell killing may
be independent of mutations and alterations in
melanoma cells, which drive the proliferation and
cause resistance to therapy.
CONCLUSION:
An immunotoxin is a human made protein that
consists of a targeting protein linked to a toxin. When
www.iajps.com
ISSN 2349-7750
endocytic compartment. Processing and trafficking of
these molecules is target and toxin specific but
ultimately results in delivery of the enzymatically
active portion of the toxin to the cytosol. The
bacterial toxins, diphtheria toxins (DT) and
pseudomonous exotoxins (PE) irreversibily modify
and inactivate Eukariyotic elongation factor 2 (eEF2),
a critical component of the protein synthesis
machinery. Plant toxins such ar gelonin and recin
also arrest protein synthesis but do so by inactivating
the ribosome instead eEF2. These toxins mediated
modification in stimulate the apoptotic pathway,
leading to cell death.
the protein binds to the cell, it is taken in through
endocytosis and the toxin kills the cell without
harming normal cells. Imunotoxin based on the
concept of targeting, cancers or tumor cells using an
antibody-toxin conjugate.
REFERENCES:
1. Lord JM, Spooner RA, Roberts LM.
Immunotoxins:
Monoclonal antibody-toxin
conjugates: A new approach to cancer therapy.
In: Monoclonal antibodies: Production and
application. Alan R. Liss, Inc., 1989: 193–211.
Page 322
IAJPS 2021, 08 (02), 318-323
2.
3.
4.
5.
6.
7.
8.
9.
Blessy M.R et al
Knowles PP, Thorpe PE. Purification of
immunotoxins containing ricin A-chain and abrin
A-chain using blue sepharose CL-6B. Analytical
Biochemistry 1987; 160: 440–3
Uckun FM, Ramakrishnan S, Houston LL.
Immunotoxin-mediated
elimination
of
clonogenic tumor cells in the presence of human
bone marrow. J Immunol 1985; 134: 2010–16.
Press OW, Vitetta ES, Farr AG, Hansen JA,
Martin PJ. Evaluation of ricin A-chain
immunotoxins directed against human T cells.
Cellular Immunology 1986; 102: 10–20.
Salvatore G., Beers R., Kreitman R. J., Pastan I.
Improved cytotoxic activity towards cell lines
and fresh leukemia cells of a mutant anti-CD22
immunotoxin obtained by antibody phage
display. Clin. Cancer Res., 8: 942-944, 2002.
Frankel A. E., Tagge E. P., Willingham M. C.
Clinical trials of targeted toxins. Semin. Cancer
Biol., 6: 307-317, 1995.
Schindler J., Sausville E. A., Messmann R., Uhr
J. W., Vitetta E. S. The toxicity of
deglycosylated ricin
A chain-containing
immunotoxins in patients with non-Hodgkin’s
lymphoma is exacerbated by prior radiotherapy:
a retrospective analysis of patients in five clinical
trials. Clin. Cancer Res., 7: 255-258, 2001.
Frankel A. E., Kreitman R. J., Sausville E. A.
Targeted toxins. Clin. Cancer Res., 6: 326334, 2000.
vanderSpek J. C., Murphy J. R. Fusion protein
toxins based on diphtheria toxin: selective
targeting of growth factor receptors of eukaryotic
cells. Methods Enzymol., 327: 239-249, 2000.
www.iajps.com
ISSN 2349-7750
10. Thompson, J., Stavrou, S., Weetall, M., Hexham,
J. M., Digan, M. E., Wang, Z., Woo, J. H., Yu,
Y., Mathias, A., Liu, Y. Y., Ma, S., Gordienko,
I., Lake, P., and Neville, D. M. Improved binding
of a bivalent single-chain immunotoxin results in
increased efficacy for in vivo T-cell depletion.
Protein Eng., in press.
11. Arora N., Masood R., Zheng T., Cai J., Smith D.
L., Gill P. S. Vascular endothelial growth factor
chimeric toxin is highly active against
endothelial
cells. Cancer
Res., 59: 183188, 1999.
12. Vallera, D. A., Li, C., Jin, N., PanoskaltsisMortari, A., and Hall, W. A. Targeting
overexpressed
urokinase-type
plasminogen
activator
receptor
(uPAR)
on
human
glioblastoma with the diphtheria toxin fusion
protein DTAT in nude mice. J. Natl. Cancer Inst.
(Bethesda), in press.
13. Liu S., Bugge T. H., Leppla S. H. Targeting of
tumor cells by cell surface urokinase
plasminogen
activator-dependent
anthrax
toxin. J. Biol. Chem., 276: 17976-17984, 2001.
14. Beers R., Chowdhury P., Bigner D., Pastan I.
Immunotoxins with increased activity against
epidermal growth factor receptor vIII-expressing
cells produced by antibody phage display. Clin.
Cancer Res., 6: 2835-2843, 2000.
15. Pai-Scherf L. H., Villa J., Pearson D., Watson T.,
Liu E., Willingham M. C., Pastan I.
Hepatotoxicity in cancer patients receiving erb38, a recombinant immunotoxin that targets the
erbB2 receptor. Clin. Cancer Res., 5: 23112315, 1999.
Page 323